면역종양학 치료제 개발의 혁신 물결

Next-gen Cell Therapies and Precision Immunotherapies are Driving Growth and New Product Development

Immuno-oncology (I-O) therapies target tumors by harnessing the host's immune system. With the growing incidence and prevalence of various types of aggressive and refractory cancers, the next-generation I-O therapy pipeline has witnessed significant growth. Chimeric antigen receptor (CAR)-T cell therapy and tumor-targeted antibody therapies, including monoclonals, antibody-drug conjugates (ADCs), bispecific antibodies, and several therapeutic cancer vaccines, are making rapid strides in clinical trials as effective immunotherapy. This study discusses the key trends and technologies driving the development of such I-O therapies. It delves into advancements in cancer vaccines and cell therapies for various cancer indications, highlighting some of the innovators in this space. Next-generation cell therapies, personalized cancer vaccines, and strategic areas of focus have also been discussed in this report. The study examines the factors driving and restraining this industry and identifies the growth opportunities emerging from the changes in this space for market players and stakeholders to leverage.

Key questions answered in this study:

•      What does the current clinical landscape of I-O therapies look like?
•      Which are the technology enablers driving the adoption of I-O therapies?
•      What are the key developments in adoptive cell therapies and cancer vaccines?
•      What are the roadblocks to successful translation?
•      What are the research and development (R&D) focus areas?
•      What are the key focus areas for the future?

Table of Contents

Strategic Imperatives

• Why Is It Increasingly Difficult to Grow? The strategic imperative 8™: Factors creating pressure on growth
• The Strategic Imperative 8™
• The Impact of the Top 3 Strategic Imperatives on the Immuno-Oncology (I-O) Therapeutics Industry
• Growth Opportunities Fuel the Growth Pipeline Engine™
• Research Methodology

Growth Environment: I-O Therapies

• Need for Immunotherapy
• Scope of Analysis
• Segmentation: Snapshot of I-O Therapies
• I-O Therapies in Development
• Growth Opportunities in I-O Therapy
• Growth Drivers
• Growth Restraints

Trends and R&D Focus: I-O Therapies

• I-O Technology Trends and Developments
• Trends in I-O Therapeutics
• Therapeutic Development Trends in I-O
• R&D Focus Areas to Boost Immunotherapies
• Modulation of TME: Solid Tumor Type Determines Therapy
• Developing Effective Preclinical Models for Translation
• Stakeholders Developing Preclinical Models for I-O Therapy Evaluation
• Holistic Tumor Profiling to Boost Precision Oncology Efforts

Emerging I-O Therapeutic Modality Development Landscape

• Quick Facts on I-O Therapies
• Clinical Development Landscape of I-O Therapies
• Cell Therapy to Create the Next Wave of I-O Developments
• Cell Therapy Types: Snapshot
• Clinical Development Landscape of I-O Cell Therapies
• Emerging Areas of Focus to Improve Functionality and Safety Cell Therapies
• Next-generation CAR-T Therapy Development
• Priority Areas to Improve the Accessibility of Cell Immunotherapy
• Innovative Technologies for Cell Therapy Manufacturing and Delivery
• Stakeholders Developing Emerging Next-gen Cell Therapies
• Potential of Vaccines to Address Challenges with Difficult-to-Treat Cancers
• Cancer Vaccine Types
• Personalized Neoantigen Vaccines in Clinical Development
• Areas of Focus to Bolster Cancer Vaccine Development
• RNA Vaccines to Drive the Wave of Prophylactic and Therapeutic Cancer Vaccines
• Road Ahead for Cancer Vaccines and Immunotherapy
• Emerging Cancer Vaccine
• Impact of Emerging Cancer Vaccines Across Cancers

I-O Stakeholder Ecosystem

• Regional Trends in I-O Developments and Adoption
• Federal Initiatives and Programs Driving I-O Therapy Development
• I-O Deals and Investment Trends
• Notable Partnerships and Collaborations in I-O, 2023

I-O Regulatory Environment and Reimbursement

• I-O: Current Gaps and Potential Opportunities
• Strategies to Improve Access and Care Delivery of I-O Therapies

Growth Opportunity Universe

• Growth Opportunity 1: Combination Immunotherapies
• Growth Opportunity 2: Precision Oncology
• Growth Opportunity 3: Advanced Synthetic Biology Platforms
• Growth Opportunity 4: Organoids and Organ-on-Chip Models

Appendix

• List of a Few Approved ADCs
• Approved CAR-T Therapies (global)

Next Steps

• Your Next Steps
• Why Frost, Why Now?
• Legal Disclaimer